Terremoto Biosciences | $108,000,000 | (Apr 16, 2026)
Ralio | $2,500,000 | (Apr 16, 2026)
Parasail | $32,000,000 | (Apr 16, 2026)
ImmuneWalk Therapeutics
United States
- Pearl River, New York
- 08/05/2025
- Seed
- $7,000,000
ImmuneWalk Therapeutics is a private clinical-stage company focused on development of novel therapies for chronic inflammatory diseases. Our Monocyte Targeting Technology (MTT) is designed to selectively block the migration (`walking`) of monocytes from the blood stream into inflamed tissues. Our lead candidate, IW-601, is a proprietary monoclonal antibody that is engineered to specifically prevent monocytes from exiting the blood stream and traveling to inflammatory sites. IW-601 is designed to offer a novel and differentiated approach in the landscape of current anti-inflammatory agents.
With clear disease-modifying activity in models of Multiple Sclerosis, Rheumatoid Arthritis, Inflammatory Bowel Disease and Non- Alcoholic Steatohepatitis, in addition to proof-of-concept from patient’s cells, we are advancing IW-601 to a Ph1 clinical trial.
- Industry Biotechnology Research
- Website https://immunewalk.com/
- LinkedIn https://www.linkedin.com/company/immunewalk-therapeutics/
spektr | $20,000,000 | (Apr 16, 2026)
Modern Relay | $3,000,000 | (Apr 16, 2026)
Paxos Labs | $12,000,000 | (Apr 16, 2026)
Gitar | $9,000,000 | (Apr 16, 2026)
STORM Therapeutics Limited | $56,000,000 | (Apr 16, 2026)
Traza | $2,100,000 | (Apr 16, 2026)
Smartwage Società Benefit | $2,000,000 | (Apr 15, 2026)
Synera | $40,000,000 | (Apr 15, 2026)
Turion Space | $75,000,000 | (Apr 15, 2026)